AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01524380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba extract
Description: 400mg/day, twice a day, 10 weeks
Study NCT03127059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises
Description: Key points in the intervention are~* Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.~* Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.~* Inclusion of the breathing modification into walking and other physical activities.~* Daily home exercise of BrEX.
Study NCT03127059 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
Study NCT03476642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
Study NCT01524380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice a day, 10 weeks
Study NCT02953041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: long-acting muscarinic antagonist
Study NCT02953041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: ultra long-acting beta agonist
Study NCT01413386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary stent
Description: palliative treatment for malignant patients
Study NCT01413386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biliary stent
Description: palliative treatment for malignant patients
Study NCT03227874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried apple
Description: diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
Study NCT03227874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muffin
Description: two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
Study NCT04003610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: 13.5 mg once a day orally
Study NCT04003610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W intravenously
Study NCT04003610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m\^2 IV over 30 minutes on Days 1 and 8 of each 3-week cycle
Study NCT04003610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dosed to target AUC of 5 mg/mL/min or 4.5 mg/mL/min if required per local guidelines on Day 1 or 2 of each 3-week cycle
Study NCT04880122 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dried blood spot and venous blood collection
Description: A paired venous blood and capillary blood sample (dried blood spot) were collected in every participant for validation purpose. Venous blood samples were analyzed using a chemiluminescent microparticle immunoassay ( the Architect i2000sr Plus system, Abbott), as a reference. Dried blood spots (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany) or (Whatman™, GE Healthcare Sciences, Cardiff, UK) were analyzed by means of a SARS-CoV-2 IgG ELISA (EUROIMMUN, PerkinElmer Health Sciences Inc., Lübeck, Germany).
Study NCT00003141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00003141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00003141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00003141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00003141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00003141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV
Study NCT00003141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00003141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00003141 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT02463461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiSleep Activity Monitor
Description: Subjects in this group will wear a ActiSleep Activity Monitor.
Study NCT02463461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jawbone Activity Monitor
Description: Subjects in this group will wear a Jawbone Activity Monitor.
Study NCT02463461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actiwatch 2 Activity Monitor
Description: Subjects in this group will wear a Actiwatch 2 Activity Monitor.
Study NCT02463461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit Activity Monitor
Description: Subjects in this group will wear a FitBit Activity Monitor.
Study NCT02463461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actigraph by Ambulatory Monitoring Activity Monitor
Description: Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
Study NCT00588367 — intervention group
Intervention type: DEVICE
Intervention: Mayo Interactive Breath Hold Monitor
Description: Biofeedback device
Study NCT02690701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home.
Study NCT02690701 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home.
Study NCT00424398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepreve
Description: sterile ophthalmic solution
Study NCT00424398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile ophthalmic solution
Study NCT00424398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate
Description: sterile ophthalmic solution
Study NCT03097380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: AZD2115
Study NCT03097380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPIRIVA
Description: Tiotropium
Study NCT03097380 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]AZ13754366
Description: Radioligand
Study NCT03097380 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [11C]AZ13754366
Description: Radioligand
Study NCT01339442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study NCT01339442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT01339442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT01190930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT01284803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an educational intervention
Description: To elaborate an educational program for the management of depression in primary care
Study NCT04268719 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: wireless pH capsule recording
Description: wireless pH capsule recording for up to 96 hours
Study NCT04178655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: 1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
Study NCT04178655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
Study NCT02345798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-Up Care
Description: Undergo usual care
Study NCT02345798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver-Related Intervention or Procedure
Description: Undergo video-assisted intervention
Study NCT02345798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Undergo video-assisted intervention
Study NCT02345798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Undergo quality of life assessment
Study NCT02345798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Undergo quality of life assessment
Study NCT02345798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Undergo questionnaire administration
Study NCT02345798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Undergo questionnaire administration
Study NCT00714779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20-40 mg / day orally
Study NCT00714779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short-term psychodynamic psychotherapy
Description: 1 session / week for 16 weeks
Study NCT02755402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xpert HCV Viral load
Description: HCV viral load testing
Study NCT02755402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transient elastography
Description: Evaluation of liver fibrosis
Study NCT01349309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing Exercise Group
Description: Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds.
Study NCT04410874 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imvamune
Description: Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10\^7, 1x10\^8, or 4x10\^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
Study NCT01082484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil
Description: Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
Study NCT01082484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
Study NCT03476642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
Study NCT01082484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
Study NCT00898092 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Study NCT00898092 — intervention group
Intervention type: GENETIC
Intervention: molecular genetic technique
Study NCT00898092 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis
Study NCT00898092 — intervention group
Intervention type: GENETIC
Intervention: polymerase chain reaction
Study NCT00898092 — intervention group
Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction
Study NCT00898092 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study NCT00539019 — intervention group
Intervention type: OTHER
Intervention: calories measured 5x following wound healing
Description: measure REE at various time points postburn
Study NCT01272583 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: 100 mg once daily for six weeks
Study NCT01272583 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: placebo, once daily for six weeks
Study NCT03700957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: 100 milligrams of Docosahexaenoic Acid
Study NCT03700957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04324853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microscopy ( Urine filtration), UCAA test, qPCR,
Description: Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode worms) of the genus Schistosoma.Schistosomiasis is prevalent in tropical and subtropical areas, especially in poor communities without access to safe drinking water and adequate sanitation.
Study NCT04324853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microscopy (Kato Katz, Coproculture, Harada Mori, MIF), qPCR,
Description: Soil-transmitted helminth infections are among the most common infections worldwide and affect the poorest and most deprived communities. They are transmitted by eggs present in human faeces which in turn contaminate soil in areas where sanitation is poor.
Study NCT02154399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV
Study NCT02154399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02154399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery/thoracotomy
Study NCT02154399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Oxygen Measurement
Description: Undergo tumor hypoxia measurement
Study NCT00749203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: single dose 0.045 mg/kg IV infused over 40 minutes
Study NCT00749203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
Study NCT01907165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT01907165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Study NCT01907165 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Copper gluconate
Study NCT01572155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus stimulation 1
Description: 2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
Study NCT01572155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus stimulation 2
Description: 2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
Study NCT02150031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% Chlorhexidine
Description: mouthwash with 10 ml for 1 minute
Study NCT01190930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00764517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT00764517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01469767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinonide cream
Description: Fluocinonide cream 0.1% applied twice daily for 5 days.
Study NCT01314417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
Study NCT00287092 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT5aP-IPV-Hib 5-component Pertussis vaccine
Description: 0.5 mL, IM
Study NCT00287092 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix® -IPV+Hib
Description: 0.5 mL, IM
Study NCT01133353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrabenazine MR
Description: Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks
Study NCT01133353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 5 tablets once per day depending on weight for 12 weeks
Study NCT03919630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Mobilization
Description: Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine
Study NCT03919630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Thrust Mobilizations
Description: Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
Study NCT02939092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomegranates peel extract
Description: Pomegranate is antimicrobial
Study NCT02939092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine mouthwash is antiplaque agent
Study NCT04446559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sitting in chair position
Description: For patients randomized in the chair group, we will perform the transfer to the chair immediately after the morning arterial blood gas. The chair position will be maintained for 3 hours, if the patient shows no clinical signs of discomfort or intolerance.
Study NCT03770598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Distressed in study Arm Distressed
Description: Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.
Study NCT03770598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Education
Description: Mindfulness based stress reduction class, yoga and education material
Study NCT03770598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Team Based Care
Description: Psychiatrist, Oncologist, clinical social worker, study coordinator
Study NCT03770598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Non-Distressed
Description: No psycho-education about wellness promotion or health. These patients will be monitored only.
Study NCT02428127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage powder
Description: Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
Study NCT02428127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calorie matched beverage powder
Description: Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
Study NCT02428127 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: lukewarm water
Study NCT05008978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 1
Description: 25g of available carbohydrates from White bread with 25g of available carbohydrates from Banana consumed simultaneously at time 0 min